Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Paraproteinemias 1Nervous System Diseases 1Kidney Diseases 1Hematologic Diseases 1Autoimmune Diseases 1

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 330Cisplatin 277Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 211Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Has results × Plasma Exchange × Clear all
NCT01210716 2013-09-23

Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device

Fenwal, Inc.

Phase 3 Completed
37 enrolled 7 charts
Genitourinary

Autoimmune Diseases, Hematologic Diseases, Kidney Diseases, Nervous System Diseases, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡